vitiligo
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: i. Consecutive patients, diagnosed with stable vitiligo vulgaris* with symmetrical vitiligo patches *Vitiligo vulgaris: a few to many widespread depigmented macules over the entire body, with often a symmetrically distribution pattern. Stable means: no expansion of existing lesions or appearance of new lesions during the previous 6 months, absence of Koebner*s phenomenon and a positive minigrafting test ii. Patients, eligible for minigrafting and NB-UVB/excimer therapy iii. Adult patients: * 18 years iv. Patients who have given written informed consent
Exclusion criteria
Exclusion criteria: Patients: i. With a history of hypertrophic scarring and/or keloid ii History of allergic/phototoxic reaction (Lidocaine, Tegaderm, Suture strips, sunlight) iii With a negative minigrafting test iv With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member) v. With a personal history of photosensitivity and/or phototoxicity disorders vi. With skin type I (according to Fitzpatrick classification I-VI) vii. Who are pregnant viii. Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (eg. tetracycline, retinoids, sulfonamids, psoralens, NSAID*s) ix. With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema. x. Who are not able to have 2 times weekly NB-UVB/Excimer therapy. xi. With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weekswill be required.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage, start and grade of repigmentation | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction | — |
Countries
Netherlands